Institutional Biosafety Committee Minutes

Date: Wednesday, September 16, 2026

Time: 9:30 AM

Location: Zoom Meeting

MEMBERS IN ATTENDANCE	MEMBERS ABSENT	STAFF
Busch, Robert H	Schnappinger, Dirk	Gonzalez Russi, Sabrina
Carroll, Ann M.		Lejb, Katarzyna
Finkernagel, Scott W.		
Geri, Jacob Benjamin		
Kaminsky, Stephen M.		
Lieggi, Christine		
McGuinn, Catherine		
Ndhlovu, Lishomwa (Lish)		
Otero, Miguel		
Repik, Gabrielle		
Wagner, John A.		

Meeting Minutes for Approval:

- August 19, 2026

No issues were raised and the committee approved the minutes from August 19, 2026.

Safety Officer Report

New Business

- New NIH Draft Biosafety Policy for Research Involving Biohazards

Conflicts of Interest Disclosure:

No member of the IBC may participate in the review or approval of any project in which the IBC member is an investigator, is or is expected to be engaged, has a financial conflict of interest, or has any other interest that adversely impacts the IBC member's ability to exercise independent judgment. Under such circumstances, the IBC member shall not be present during IBC deliberations, except to provide information requested by the IBC to facilitate the IBC's review. Although such members must recuse themselves from the final determination related to the project, they may be counted for purposes of establishing a voting quorum for the meeting. Each member of the IBC shall respect and preserve the confidentiality of information he/she receives as a member of the IBC, and shall use, discuss, and/or disclose such information only for purposes related to deliberations or other assigned business of the IBC.

- *Dr. Otero reported a Conflict of Interest with Dr. Blobel and Dr. Lu. Dr. Otero will abstain from voting on these*

registrations.

Protocols on Agenda

The Institutional Biosafety Committee (IBC) and Biosafety staff perform pre-reviews on all protocol submissions, including consideration of: agent characteristics (e.g., virulence, pathogenicity, environmental stability, replication competence), the types of manipulations planned, the sources of nucleic sequences (species), the nature of the nucleic acid sequences (e.g., structural, enzyme, oncogene, toxin, gene regulator), the hosts and vectors to be used, whether an attempt will be made to obtain expression of a transgene, and if so, the function of the protein in the proposed system.

IBC review includes: (i) independent assessment and setting of the containment levels required by the NIH Guidelines for the proposed research; (ii) assessment of the facilities, procedures, practices, and training and expertise of personnel involved in recombinant or synthetic nucleic acid molecule research; (iii) for recombinant or synthetic nucleic acid molecule research involving human research participants assessment focused on biosafety issues (e.g., administration, shedding) (iv) set containment levels in concert with the WCM IACUC.

Prior to reviewing a registration at the IBC meeting, the Principal Investigators laboratory is inspected to confirm that facilities and biocontainment equipment (e.g., certified Class II biological safety cabinets) are available and appropriate. We also determine if all laboratory personnel are appropriately trained to adhere to institutional and federal regulations to ensure the safe and compliant conduct of research.

All protocol submissions are made available to IBC members before the meeting. During the meeting, reviewers' and members' questions are presented, discussed, and sufficiently addressed. Protocols are voted on and acted upon by the IBC, i.e., applications are either approved, rejected or returned to the applicant to request clarifying information. Protocols deemed to require changes are returned to the PI for revision before subsequent review by the IBC. Principal Investigators are then provided the results of the IBC review and official approval.

Following initial approval, IBC registration remains valid for a period of two years. During this two-year period, laboratory inspections and review of training records of lab staff are conducted annually in accordance with Weill Cornell policies.

Laboratory Safety Registrations - Amendments

Record Number: 20-0156
PI Name: Benjamin Kleaveland
Submission Type: Amendment
Notes: The assigned IBC member reviewed the lab protocol. The amendment includes new recombinant transgenes and adenoviral vectors to study the importance of RTL1 in myoblast cell lines and/or primary myoblast cultures. No issues were raised. The reviewer recommends approval at previously approved biosafety levels and Adenovirus to be approved at BSL-2.
Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/sero types for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed /planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		Ad5	Replication Incompetent/ Deficient	N/A, purchased	In Vitro	In vivo model	cre recobinase	Bacteriophage	Other/ excision of floxed alleles	Transfect cell line ~ Transfect cells	BSL-2	NIH Applicable	Section II I-D-1

Record Number: 21-0074

PI Name: Michael Podolsky
Submission Type: Amendment
Notes: The assigned IBC member reviewed the lab protocol. The amendment includes the addition of using LPS as a toxin to induce preterm birth in mouse to explore the role of collagen turnover in regulating preterm birth. No issues were raised. The reviewer recommends approval at previously approved biosafety levels and E. Coli to be approved at BSL-2/ABSL-2.
Decision: Approved

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Escherichia Coli		LPS only derived from E.coli 0111: B4	Replication Incompetent/Deficient	In Vivo	Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	

Laboratory Safety Registrations - 2-Year Renewals

Record Number: 19-0257
PI Name: Iliyan D Iliev
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer suggested changing the work with Clostridium to in vitro only. Additionally, the reviewer requested clarification if inactivated COVID-19 patient sample work is still part of the laboratories' research. No other issues were raised. With these administrative changes, the reviewer recommends approval at previously approved biosafety levels and Citrobacter rodentium to be approved at BSL-1/ABSL-1.
Decision: Approved with administrative changes

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Salmonella [Typhimurium]		Typhimurium	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Epicoccum [Spp.]		Nigrum	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Wallemia [Sebi]		Sebi	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Malassezia [Spp.]		Restricta	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Clostridium [Spp.]	Clostridia	clostridia Mixed culture of 17 strains	Replication Incompetent/Deficient	In Vitro	Culturing ~ Other/ Will be used to study fungal/ bacterial interactions	BSL-1	Not rDNA	
Saccharomycopsis [Fibuligera]		Fibuligera	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Candida [Spp.]		Auris, glabrata, duobushaemulonii, haemulonii, ohmeri, krusei, lusitaniae	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Trichosporon [Spp.]	mucoides	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Kazachstania	pintolopesii	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Nippostrongylus [Brasiliensis]		Nippostrongylus brasiliensis	Replication Competent	In Vivo	Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	

Rhodotorula		Mucilaginosa	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Cladosporium [Spp.]		Cladosporioides	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Aspergillus [Spp.]		Versicolor, sydowii, amstelodami	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Candida [Spp.]		Albicans, tropicalis, parapsilosis, pintolopesii, kudriavzevii	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Citrobacter [Rodentium]		Rodentium	Replication Incompetent/Deficient	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	

- - - - - - - - - - - - - -

Record Number: 19-0261
PI Name: Chun-Jun Guo
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer requested to uncheck replication incompetent/deficient and to change the work to be used in vitro and in vivo for Enterococcus Faecium ATCC 700221. No other issues were raised. With these administrative changes, the reviewer recommends approval at previously approved biosafety levels.
Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Clostridium [Spp.]		Sporogenes (ATCC 15579), Clostridium bolteae, Clostridium sp. 7_2_43FAA, Blauti hydrogenotrophica, Blauti luti, Clostridium hatehwayi, Clostridium innocuum, Clostridium parapurtrificum, Clostridium symbiosum, Eubacterium limosum, Eubacterium maltosivorans, Eubacterium ramulus, Roseburia inulinivorans, Eubacterium sp., Clostridium saccarolyticum,	Replication Competent	Sporogenes (ATCC 15579), Clostridium bolteae, Clostridium sp. 7_2_43FAA, Blauti hydrogenotrophica, Blauti luti, Clostridium hatehwayi, Clostridium innocuum, Clostridium parapurtrificum, Clostridium symbiosum, Eubacterium limosum, Eubacterium maltosivorans, Eubacterium ramulus, Roseburia inulinivorans, Eubacterium sp., Clostridium saccarolyticum,	Both	In vivo model	Aminotransferase, ammonia-lyase, dehydratase	Bacteria	Other/ Aminotransferase, amonia-lyase, dehydratase	Direct inject into in vivo	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-4
Bacteroides [Spp.]		Bacteroides theta, Bacteroides ovatus, Bacteroides SP. 1_1_6, Bacteroides cellulosilyticus, Bacteroides dorei, Bacteroides eggerthii, Bacteroides finegoldii, Bacteroides intestinalis, Bacteroides nordii, Bacteroides salyersiae, Bacteroides uniformis, Parabacteroides faecis, Parabacteroids merdae, Prevotella bivia, Prevotella stercorea, Prevotella corporis, Paraprevotella clara,	Replication Competent	Bacteroides theta, Bacteroides ovatus, Bacteroides SP. 1_1_6, Bacteroides cellulosilyticus, Bacteroides dorei, Bacteroides eggerthii, Bacteroides finegoldii, Bacteroides intestinalis, Bacteroides nordii, Bacteroides salyersiae, Bacteroides uniformis, Parabacteroides faecis, Parabacteroids merdae, Prevotella bivia, Prevotella stercorea, Prevotella	In Vivo	Bacteria 1	Aminotransferase, amonia-lyase, dehydratase	Bacteria	Other/ Aminotransferase, amonia-lyase, dehydratase	Direct inject into in vivo	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-4

		Prevotella histicola, Prevotella sp. , Prevotella baroniae, Prevotella marshii, Prevotella rara		corporis, Paraprevotella clara, Prevotella histicola, Prevotella sp. , Prevotella baroniae, Prevotella marshii, Prevotella rara									

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism f or Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Enterococcus [Spp.]		faecium (ATCC70 0221)	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Clostridium [Spp.]		Difficile strain 630 (ATCC BAA-1382)	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Salmonella [Typhimurium]		S. Typhimurium A TCC14028 (?aroA)	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Clostridium [Spp.]		Sporogenes (ATCC 15579), Clostridium bolteae, Clostridium sp. 7_2_43 FAA, Blauti hydrogenotrophica	Replication Competent	Both	Culturing ~ Introduction into in vivo ~ Isolation DNA/RNA	ABSL-2 ~ BSL-2	Not rDNA	
Bacteroides [Spp.]		Bacteroides theta, Bacteroides ovatus, Bacteroides cellulosilyticus	Replication Competent	Both	Culturing ~ Introduction into in vivo ~ Isolation DNA/RNA	ABSL-2 ~ BSL-2	Not rDNA	

- - - - - - - - - - - - - -

Record Number: 19-0352
PI Name: Annarita Di Lorenzo
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer requested to indicate the removal of Amphotropic Retroviral work in the Changes to the IBC Laboratory Registration section of the eForm. No other issues were raised. With this minor administrative change, the reviewer recommends approval at previously approved biosafety levels.
Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		pLenti	Replication Incompetent/ Deficient	293T cells	In Vitro	In vivo model~ Human	vascular endothelial cadherin, Nogo-B	Human ~ Murine	Gene Expression Regulators	Create virions ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3

- - - - - - - - - - - - - -

Record Number: 19-0443
PI Name: Randy Longman
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.
Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/ vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		pLKO	Replication Incompetent/ Deficient	293T	In Vitro	Human	library of human shRNA	Human ~ Murine	Marker/ Reporter	Other/shRNA transduction ~ Repress/ Downregulate gene of interest	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3
Escherichia Coli		E. coli (pathogenic) Human-derived, C UMT8 (mouse-derived), NC1 01 (mouse-derived)	Replication Competent	Human-derived, CUMT8 (mouse-derived), NC101 (mouse-derived)	In Vivo	In vivo model~ Human	pdu operon, fucA, fucO, colV, chuA, eut, SFB3340, OT2	Bacteria	Cytokine	Express/ Upregulate gene of interest	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-4

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Citrobacter [Rodentium]		Citrobacter rodentium ATCC 51459	Replication Competent	Both	Conduct Multiplicity of infection (MOI) studies ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Enterococcus [Aerogenes/Cloacae]		Enterococcus	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Clostridium [Spp.]		Clostridium difficile	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Listeria [Monocytogenes]		Monocytogenes	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Influenza Virus [Orthomyxoviridae Types A, B, C (Vaccine Strain)]		A/PR8	Attenuated ~ Replication Competent	In Vitro	Conduct Multiplicity of infection (MOI) studies ~ Introduction into in vivo	BSL-2	Not rDNA	
Salmonella [Typhimurium]		Typhimurium	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
Bacteroides [Spp.]		normally commensal	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Helicobacter hepaticus	ATCC 51449	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	

- - - - - - - - - - - - -

Record Number: 19-0721
PI Name: Gregory F Sonnenberg
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. The reviewer requested to add gavage as a route of administration to Human derived microbiota, Helicobacter hepaticus, and Dubosiella newyorkensis. The reviewer also noted that Dubosiella muris and Dubosiella newyorkensis need to be added to the PI's IACUC protocol. No other issues were raised. With these administrative changes, the reviewer recommends approval at previously approved biosafety levels and Helicobacter hepaticus to be approved at BSL-2/ABSL-1.
Decision: Approved with administrative changes

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Salmonella [Typhimurium]		AroA	Replication Competent	Both	Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	

*Other	Dubosiella Muris	NM09_H32	Attenuated ~ Replication Incompetent/Deficient	Both	Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
*Other	Human derived microbiota	Human microbiota isolated from our biobank	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Dubosiella newyorkensis	Erysipelotrichaceae gen. nov isolate NM09_H32	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
Citrobacter [Rodentium]		Citrobacter rodentium	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-1	Not rDNA	
*Other	Helicobacter hepaticus	American Type Culture Collection 51449	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-1 ~ BSL-2	Not rDNA	

- - - - - - - - - - - - - -

Record Number: 19-0725
PI Name: Dilek Colak
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted the addition of AAV work to this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.
Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adeno-Associated Virus (AAV)		AAV5, pAAV-CaMKIIa-EGFP, AAV-PHP.eb-GlGYF1 shRNA (VectorBuilder)	Replication Incompetent/ Deficient	N/A	Both	In vivo model	enhanced GFP	Murine	Marker/ Reporter	Direct inject into in vivo ~ Express/Upregulate gene of interest	ABSL-1 ~ BSL-1	NIH Applicable	Section II I-D-4 ~ Section III-E-1

- - - - - - - - - - - - - -

Record Number: 19-0741
PI Name: Carl P. Blobel
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.
Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines

Retrovirus [Amphotropic]		pMSCV-neo retrovirus, Murine Stem Cell Virus System,TaKaRa/Clontech	Replication Incompetent/Deficient	PT67 packaging cell line	In Vitro	In vivo model~ Bacterial ~ Human	ADAM (9, 10, 12, 15, 17, 19), TNF, TGF, EGF, HB-EGF, amphiregulin, epiregulin, epigen, betacellulin, Notch 1, Notch 4, Kit ligand 2, iRhom 1, iRhom2, Human ACE2 cDNA for work with retroviral expression. Since ADAMs 10 and 17 have many substrates that are membrane proteins, we also obtain cDNAs encoding for such substrate proteins (e.g the LDL-receptor, or the FGF-receptor 2) to test whether they can be cleaved by ADAM10 or ADAM17.	Human ~ Murine ~ Other/ Drosophila	Cytokine ~ Gene Expression Regulators ~ Marker/Reporter ~ Other/ Metalloproteinase	Create virions ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line ~ Transfect cells ~ Transfect cells / introduce into in vivo	BSL-2+	NIH Applicable	Section II I-D-1
Lentivirus [Retroviridae/ Lentiviridae]		PLVX-PURO	Self-Inactivating	293T cells	In Vitro	In vivo model~ Human	ADAM (9, 10, 12, 15,17, 19), TNF, TGF, EGF, HB-EGF, amphiregulin, epiregulin, epigen, betacellulin, Notch 1, Notch 4, Kit ligand 2, iRhom1, iRhom2, Adeno5 E40RFI, myristoylated Akt, Human ACE2 cDNA, cDNA for human ACE2 and the cDNA for Corona virus Spike proteins from coronavirus isolates (SARSCoV protein (2002), COVID-19/SARS-CoV-2-S protein, HN63-CoV-S protein). If other Coronavirus S-protein cDNAs become available, we would also like to obtain and test these. The safety considerations should be the same for all recombinant S-proteins (no live or attenuated virus will be used).	Human ~ Murine ~ Other/ Adenovirus, coronavirus, drosophila ~ Virus	Cytokine ~ Gene Expression Regulators ~ Hormone ~ Other/ Metalloproteinase, cytokines, signaling molecules	Create virions ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line ~ Transfect cells ~ Transfect cells / introduce into in vivo	BSL-2+	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Record Number: 19-0743
PI Name: Theresa T. Lu
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. During IBC renewal review, the lab confirmed that work with COVID related materials is no longer being used and therefore, this falls into the No-IBC applicable section. No other issues were raised. With this administrative change, the reviewer recommends approval.
Decision: Approved with administrative changes

Record Number: 19-0744
PI Name: Inez Rogatsky
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted that one mouse line was added to this renewal. The reviewer suggested removing the repeated risk language in the Additional Risk associated with the agent section of the eForm. No other issues were raised. With this minor administrative change, the reviewer recommends approval at previously approved biosafety levels.
Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/Lentiviridae]		2nd gen Backbone psPAX2: gag, pol, rev tat. ps-MYC-VSV-G is empty backbone.	Replication Incompetent/Deficient ~ Self-Inactivating	HEK293T	In Vitro	In vivo model~ Human	GRIP1 and its mutated for ms; shRNA for GRIP1	Human ~ Murine	Gene Expression Regulators	Create virions ~ Express/Upregulate gene of interest ~ Repress/ Downregulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Record Number: 19-0746
PI Name: Jane E. Salmon
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.
Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adenovirus [Human, all types]		pAd-Track-CMV	Replication Incompetent/ Deficient	293A	Both	Human	Apolipoprotein M, Interferon Alpha	Human ~ Murine	Cytokine ~ Gene Expression Regulators	Create virions ~ Express/Upregulate gene of interest ~ Transfect cell line ~ Transfect cells / introduce into in vivo	ABSL-2 ~ BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3 ~ Section III-D-4

Record Number: 22-0020
PI Name: Timothy Niewold
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.
Decision: Approved

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Lentivirus [Retroviridae/ Lentiviridae]		Gibco LV-MAX kit	Replication Incompetent/ Deficient	HEK293 cell lines	In Vitro	In vivo model~ Human	APOL1, PNP	Human	Other/Murine	Express/ Upregulate gene of interest ~ Repress/Downregulate gene of interest ~ Transfect cell line	BSL-2	NIH Applicable	Section II I-D-1 ~ Section III-D-3

Record Number: 22-0069
PI Name: Nicholas Collins
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted no changes associated with this renewal. No issues were raised. The reviewer recommends approval at previously approved biosafety levels.
Decision: Approved

Biological/Microbiological Microorganism Tracking Table:

Biological/Microbiological Microorganism Tracking Table:

Microorganism for Biological/Microbiological work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	In vivo or in vitro?	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
*Other	Yersinia Pseudotuberculosis	YopM (from WT 32777). For source and attenuation info please refer to overview of lab research	Attenuated	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Staphylococcus epidermidis	NIH LM087	Replication Competent	Both	Conduct Multiplicity of infection (MOI) studies ~ Culturing ~ Introduction into in vivo ~ Isolation DNA/RNA	ABSL-2 ~ BSL-2	Not rDNA	
*Other	Yersinia Pseudotuberculosis	wild type strain 32777. Source is James Bliska (Dartmouth)	Replication Competent	Both	Culturing ~ Introduction into in vivo	ABSL-2 ~ BSL-2	Not rDNA	

- - - - - - - - - - - - - -

Record Number: 25-0001
PI Name: Mohammad Arifuzzaman
Submission Type: Renewal
Notes: The assigned IBC member reviewed the lab protocols and noted the minor change of administrative contact. The reviewer requested more information on the Bacteroides ovatus strain used, specifically its ability to replicate. No other issues were raised. With this administrative change, the reviewer recommends approval at previously approved biosafety levels.
Decision: Approved with administrative changes

Recombinant Microorganism Tracking Table:

Recombinant Microorganism Tracking Table:

Microorganism for Recombinant work	Other microorganism name	List strains/serotypes for constructs	Ability to replicate in the cell	Cell/cell type where microorganism/vector will be propagated/packaged	In vivo or in vitro?	Cell type where expressed	Gene/gene family to be inserted, deleted, upregulated or downregulated	Original source(s) species of DNA/RNA	Biological activity/potential of gene modification	Manipulation types performed/planned	Assigned Biosafety Level(s)	Regulatory Rationale	Applicable NIH Guidelines
Adeno-Associated Virus (AAV)		AAV-PHP.eb-CAG-mCherry, AAV-PHP.eb-CAG-CRE	Replication Incompetent/ Deficient	Not propagated	In Vivo	In vivo model	mCherry, Cre recombinase	Virus	Gene Expression Regulators ~ Marker/Reporter	Direct inject into in vivo	ABSL-1	NIH Applicable	Section II I-D-4
Bacteroides [Spp.]		Bacteroides ovatus	Replication Competent	Not propagated	In Vivo	In vivo model	Bile salt hydrolase (Bsh) (deletion)	Bacteria	Other/metabolic enzyme	Direct inject into in vivo	ABSL-2~ BSL-2	NIH Applicable	Section III-D-1~Section III-D-4

- - - - - - - - - - - - - -

Acknowledgement of Laboratory Safety Registrations: No IBC-Applicable Work Conducted

Record Number	PI Name	Laboratory Safety Registration Submission Type
19-0742	Mary K Crow	Lab Registration - Renewal

Laboratory Safety Registrations: Exempt

Record Number	PI Name	Laboratory Safety Registration Submission Type
26-0055	Sven Lange	Lab Registration - Initial

Request for Extension of Expiration Date to October 21, 2026

Record Number	PI Name
20-0159	Ype P. de Jong
19-0736	Estomih P. Mtui
19-0720	David Artis
23-0143	Krystyn Van Vliet

The meeting adjourned at 10:35 AM.